Literature DB >> 11923687

Serum anti-pig antibodies as potential indicators of acute humoral xenograft rejection in pig-to-cynomolgus monkey kidney transplantation.

Andrew C Richards1, Hugh F S Davies, Megan L McLaughlin, Laura S Copeman, Beverly J Holmes, Gabriela Dos Santos Cruz, Sandhya Bycroft, Gilda Chavez, David J G White, Henk-Jan Schuurman, Emanuele Cozzi.   

Abstract

BACKGROUND: Hyperacute rejection of solid organ pig xenografts in nonhuman primates has been overcome by using donors transgenic for human complement regulatory proteins, but grafts are still susceptible to humoral (antibody-mediated) rejection. We investigated whether circulating xenoreactive antibodies are a useful indicator of this xenograft rejection.
METHODS: Five assays were employed in a retrospective analysis on 20 selected cynomolgus monkey recipients of renal xenografts transgenic for human decay-accelerating factor, with survival between 4 and 60 days. The assays included hemolytic and hemagglutination assays and the measurement of immunoglobulin (Ig)G and IgM binding to porcine endothelial cells and leukocytes, and to the Gal alpha 1-3Gal trisaccharide (Gal) antigen. To assess non-Gal-directed antibodies, sera were absorbed with a Gal-coated resin. A predictive value was defined as an increase in antibody levels before a decline in graft failure (>20% increase in creatinine levels) and humoral rejection in graft pathology.
RESULTS: Data on hemolytic anti-pig antibody correlated with those on IgM antibody to endothelial cells, leukocytes, and Gal. In absorbed sera IgM and IgG antibody to endothelial cells and leukocytes correlated with each other, indicative for an elicited antibody response to non-Gal antigens. Sixteen animals showed humoral rejection, and in all but two animals one or more assays was considered of predictive value. On the other hand, increased antibody levels were noted in two animals without signs of rejection in graft pathology and in two cases with cellular xenograft rejection.
CONCLUSIONS: It is recommended to use multiple assays (preferably hemolytic, anti-Gal, and anti-endothelial cell) to be able to fully monitor the peripheral antibody responses in pig-to-primate xenograft recipients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923687     DOI: 10.1097/00007890-200203270-00009

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Antiendothelial cell antibodies in vasculitis and connective tissue disease.

Authors:  C Belizna; A Duijvestijn; M Hamidou; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

2.  Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function.

Authors:  P Thompson; I R Badell; M Lowe; J Cano; M Song; F Leopardi; J Avila; R Ruhil; E Strobert; G Korbutt; G Rayat; R Rajotte; N Iwakoshi; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2011-08-29       Impact factor: 8.086

Review 3.  The role of B cells in solid organ transplantation.

Authors:  Jean Kwun; Pinar Bulut; Eugenia Kim; Wasim Dar; Byoungchol Oh; Ravi Ruhil; Neal Iwakoshi; Stuart J Knechtle
Journal:  Semin Immunol       Date:  2011-12-01       Impact factor: 11.130

4.  Xenotransplantation: Progress Along Paths Uncertain from Models to Application.

Authors:  Jeffrey L Platt; Marilia Cascalho; Jorge A Piedrahita
Journal:  ILAR J       Date:  2018-12-31

5.  Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies.

Authors:  G L Palmisano; P L Tazzari; E Cozzi; A Bolognesi; L Polito; M Seveso; E Ancona; F Ricci; R Conte; F Stirpe; G B Ferrara; M P Pistillo
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

6.  Unexpected immunoresponse to Gal and APA antigens in diabetic type 1 patients receiving neonatal pig islets after 6 years.

Authors:  Rafael A Valdés-González; Luis M Dorantes; G Nayely Garibay; Eduardo Bracho-Blanchet; Roberto Dávila-Pérez; Luis Terán; Christopher E Ormsby; Jorge-Tonatiuh Ayala-Sumuano; Laura Copeman; David J G White
Journal:  J Clin Immunol       Date:  2007-03-15       Impact factor: 8.542

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.